Predictive immune markers in advanced melanoma patients treated with ipilimumab
Standard
Predictive immune markers in advanced melanoma patients treated with ipilimumab. / Umansky, Viktor; Utikal, Jochen; Gebhardt, Christoffer.
In: ONCOIMMUNOLOGY, Vol. 5, No. 6, 06.2016, p. e1158901.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Predictive immune markers in advanced melanoma patients treated with ipilimumab
AU - Umansky, Viktor
AU - Utikal, Jochen
AU - Gebhardt, Christoffer
PY - 2016/6
Y1 - 2016/6
N2 - Myeloid-derived suppressor cells (MDSCs) and chronic inflammatory factors induce immunosuppression and disease progression in advanced melanoma patients. They could serve as important markers allowing the identification of patients with high risk of melanoma progression as well as the detection of those patients who may benefit from the therapy with ipilimumab.
AB - Myeloid-derived suppressor cells (MDSCs) and chronic inflammatory factors induce immunosuppression and disease progression in advanced melanoma patients. They could serve as important markers allowing the identification of patients with high risk of melanoma progression as well as the detection of those patients who may benefit from the therapy with ipilimumab.
KW - Journal Article
U2 - 10.1080/2162402X.2016.1158901
DO - 10.1080/2162402X.2016.1158901
M3 - SCORING: Journal article
C2 - 27471626
VL - 5
SP - e1158901
JO - ONCOIMMUNOLOGY
JF - ONCOIMMUNOLOGY
SN - 2162-402X
IS - 6
ER -